How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

224 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. (Abstract)

Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. To investigate the effect of once-daily (QD) eslicarbazepine acetate (ESL) 800 mg and 1,200 mg administration on pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive (OC) in women of childbearing potential.Two two-way, crossover, two-period, randomized, open-label studies were performed in 20 healthy female subjects, each

2013 Epilepsy research Controlled trial quality: uncertain

82. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. (Abstract)

Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. To investigate the effect of eslicarbazepine acetate (ESL) on the pharmacokinetics of simvastatin (SMV), a known CYP3A4 substrate, in healthy subjects.Single centre, two-way cross-over, randomized, open-label study in 24 healthy volunteers. The volunteers received an oral single-dose of SMV 80mg on two occasions (once administered alone and once after treatment with an oral

2013 Epilepsy research Controlled trial quality: uncertain

83. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. (Abstract)

Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. To evaluate the long-term safety, tolerability and efficacy of once-daily eslicarbazepine acetate (ESL) as adjunctive therapy in adults with partial-onset seizures.One-year open-label extension (OLE) study with ESL in patients who completed a randomised, double-blind placebo-controlled trial (study BIA

2013 Epilepsy research Controlled trial quality: uncertain

84. Eslicarbazepine

Eslicarbazepine Eslicarbazepine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Eslicarbazepine Eslicarbazepine Aka: Eslicarbazepine (...) such as and Hormonal contraceptives Eslicarbazepine decreases the contraceptive efficacy Use alternative, non-hormonal agents or backup VII. Resources Medscape VIII. References (2014) Presc Lett 21(11): 65 Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Eslicarbazepine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications aptiom (on 4/19/2017 at ) APTIOM

2015 FP Notebook

85. Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01527513 Recruitment Status : Completed First Posted : February 7, 2012

2012 Clinical Trials

86. Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01532726 Recruitment Status : Completed First Posted : February 14, 2012 Last Update Posted : January 6, 2017 Sponsor: Bial - Portela C

2012 Clinical Trials

87. Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01422720 Recruitment Status : Completed First Posted : August 24, 2011 Results

2011 Clinical Trials

88. Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study. (Abstract)

Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study. This study investigated the effect of eslicarbazepine acetate (ESL) on cardiac repolarization in healthy adult volunteers. A randomized, placebo/active-controlled, 4-period crossover study was conducted in 67 participants. In 3 periods, participants received once-daily doses of ESL 1200 mg, ESL 2400 mg, and placebo for 5 days; in 1 period, participants received placebo on days 1 to 4 and a 400-mg

2011 Journal of clinical pharmacology

89. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. (Abstract)

In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Antiepileptic drugs (AEDs) are widely used not only in the treatment of epilepsy but also as treatments for psychiatric disorders. Pharmacoresistance of AEDs in the treatment of epilepsy and psychiatric disorders is a serious problem. Transport of antiepileptic drugs by P-glycoprotein (Pgp, ABCB1, or MDR1), which is overexpressed in the blood-brain barrier (...) reaction (PCR) and immunofluorescent staining. Rhodamine-123 uptake was also determined.Pgp did not transport carbamazepine, but it did transport its active metabolite carbamazepine-10,11-epoxide. Pgp also pumped eslicarbazepine acetate and oxcarbazepine, as well as their active metabolite (S)-licarbazepine. Transport of the drugs was in the order of ESL>OXC>S-LC>CBZ-E in concentration equilibrium conditions. The transport of these drugs was blocked by Pgp inhibitors tariquidar and verapamil.All

2011 Epilepsia

90. Brivaracetam (Briviact) for use in the treatment of patients with refractory epilepsy

of licence extension: 11 July 2018 Comparator(s) The comparators included in the company submission are: • eslicarbazepine acetate (Zebinix ® ) • lacosamide (Vimpat ® ) • oxcarbazepine (Trileptal ® ) • zonisamide (Zonegran ® ) Limited submission details • The limited submission criteria were met based on a minor licence extension and anticipated minimal budgetary impact in NHS Wales Clinical effectiveness • Brivaracetam (Briviact ® ) has previously been recommended by the All Wales Medicines Strategy (...) 3387. Page 2 of 3 expected that brivaracetam would potentially displace lacosamide, zonisamide, oxcarbazepine or eslicarbazepine acetate (the latter three are licensed for children above 6 years of age). Brivaracetam is reported to be useful in people who have responded to levetiracetam but had behavioural or other side effects that have led to its cessation. • The paediatric licence extension was based on the extrapolation of efficacy data from clinical studies in patients aged 16 years and above

2019 All Wales Medicines Strategy Group

91. Brivaracetam (epilepsy) - Benefit assessment in accordance with §35a Social Code Book V

questions for the benefit assessment of brivaracetam Research question Indication ACT a 1 Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in children and adolescents age = 4 to < 16 years with epilepsy Individualized adjunctive epilepsy treatment to the extent medically indicated and in the absence of known drug resistance/intolerance or contraindications, using one of the following drugs: Eslicarbazepine b , gabapentin b , lacosamide, lamotrigine (...) -onset seizures with or without secondary generalization in children and adolescents age = 4 to < 16 years with epilepsy Individualized adjunctive epilepsy treatment to the extent medically indicated and in the absence of known drug resistance/intolerance or contraindications, using one of the following drugs: Eslicarbazepine b , gabapentin b , lacosamide, lamotrigine, levetiracetam, oxcarbazepine b , topiramate, valproic acid, zonisamide b Treatment specified by the physician under consideration

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

94. Oxcarbazepine

of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Top results for oxcarbazepine 1. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide (...) and oxcarbazepine Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized (...) , double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A CRD summary The authors concluded that antiepileptic drugs may cause neurological adverse events in patients with drug resistant epilepsy, which can limit their use and impair treatment success; higher doses of oxcarbazepine were associated

2018 Trip Latest and Greatest

95. Brivaraceta

that the indirect comparisons on brivaracetam versus lacosamide, eslicarbazepine and the joint analysis of the studies on lacosamide and eslicarbazepine submitted by the pharmaceutical company (hereinafter referred to as “the company”) in the dossier were not usable [1]. On the one hand, not all studies with brivaracetam were relevant for the benefit assessment; on the other, most studies included by the company were not sufficiently similar for the indirect comparisons. In addition, the company had

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

97. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-onset Epilepsy

as monotherapy, and how does their efficacy and tolerability compare with those of older antiepileptic drugs (AEDs)? • Clobazam (CLB) • Lacosamide • Perampanel • Topiramate (TPM) • Eslicarbazepine • Lamotrigine (LTG) • Pregabalin (PGB) • Vigabatrin (VGB • Felbamate (FBM) • Levetiracetam (LEV) • Rufinamide • Zonisamide (ZNS) • Gabapentin (GBP) • Oxcarbazepine (OXC) • Tiagabine Recommendations for monotherapy in adults with new-onset epilepsy with focal epilepsy or unclassified tonic-clonic seizures Level (...) extrapolation of efficacy across populations and granted approval of eslicarbazepine and lacosamide (oral only for pediatric age group) as add-on or monotherapy for focal epilepsy in persons =4 years old and perampanel as monotherapy for focal epilepsy. FBM and VGB are not recommended in new-onset epilepsy for clinical use due to serious AEs, as there are other agents that are both safe and efficacious. This guideline was co-developed with the American Epilepsy Society. American Academy of Neurology, 201

2018 American Academy of Neurology

98. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy

) effective as adjunctive therapy in reducing seizure frequency? Level Recommendation* Level A For treatment-resistant adult focal epilepsy (TRAFE), immediate-release pregabalin (PGB) and perampanel (PER) are established as effective to reduce seizure frequency. Level B Lacosamide (LCM), eslicarbazepine (ESL), and extended-release topiramate use should also be considered to decrease seizure frequency in this population. Level A Vigabatrin (VGB) and rufinamide (RFN) should be considered established (...) effective in reducing seizure frequency when used as monotherapy? Level Recommendation Level C Eslicarbazepine use may be considered to decrease seizure frequency as monotherapy for TRAFE. Level U Data are insufficient to recommend the use of second- and the other third-generation AEDs as monotherapy in TRAFE. For adult and pediatric patients with TR generalized epilepsy (GE), are these AEDs effective in reducing seizure frequency when used as adjunctive therapy (compared with no adjunctive therapy

2018 American Academy of Neurology

99. Antiepileptic drugs: updated advice on switching between different manufacturers? products

For these drugs, there are clear indications that clinically relevant differences between different manufacturers’ products might occur, even when the pharmaceutical forms are the same and bioequivalence has been shown Ensure that the patient is maintained on a specific manufacturer’s product. Category 2 Clobazam, Clonazepam, Eslicarbazepine, Lamotrigine, Oxcarbazepine, Perampanel, Retigabine, Rufinamide, Topiramate, Valproate, Zonisamide Drugs that do not fit into Category 1 or 3 Base the need for continued

2017 MHRA Drug Safety Update

100. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine

-B*15:02 frequency is much lower in Japanese ( >> DRESS) combined are most favorable for European populations, and they are estimated at 43% and 47, respectively. 31 Limited, if any, evidence exists to support an association between HLA-A*31:01 and hyper- sensitivity associated with other aromatic anticonvulsants, including lamotrigine, 32 oxcarbazepine, eslicarbazepine, phenytoin, fospheny- toin, and phenobarbital, and thus no recommendations can be given regarding the safety of these agents (...) ). These recommendations hold irrespective of the patient’s region of origin or ethnic group. For patients who are HLA-B*15:02 negative, carbamazepine or oxcarbazepine may be prescribed per standard guidelines. If a patient is carbamazepine-na€ ive or oxcarbazepine-na€ ive and HLA-B*15:02 positive, carbamazepine and oxcarbazepine should be avoided, respectively, due to the greater risk of SJS/TEN. Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, phenyt- oin, fosphenytoin, and phenobarbital, have

2017 Clinical Pharmacogenetics Implementation Consortium

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>